MENLO PARK, Calif., Sept. 3 /PRNewswire/ — ForteBio®, Inc.,
a leading supplier of label-free technology that accelerates the
development of biotherapeutic and pharmaceutical products, today
announced the launch of its Dip and Read™ Protein G biosensor
for rapid detection and quantification of numerous types of
mammalian immunoglobulin (IgG), an antibody molecule, from
solution. Because it runs on the company’s label-free Octet
instrumentation platform, the new biosensor enables such
measurements with unprecedented speed, ease of use and
cost-efficiency. The company also announced that it has completed
International Standards Organization (ISO) certification of its
biosensor manufacturing facility.
“Protein G uniquely binds to many mammalian IgGs, such as
murine, goat, bovine and other IgGs, making it an important tool in
antibody discovery, cell line development and production
monitoring,” said Christopher Silva, ForteBio’s vice president of
marketing. “Traditional IgG quantification methods for numerous
species and subtypes using Protein G, however, are complicated,
labor-intensive and time-consuming. Now, with ForteBio’s new
Protein G biosensor, researchers can obtain highly specific binding
information in real time, in a cost-effective and easy-to-use
manner.” Mr. Silva also noted that the company’s Protein G
biosensor can be regenerated and reused, for increased workflow
flexibility and cost-efficiency.
The new biosensor comes with recombinant Protein G
pre-immobilized on the surface and is ready to use on ForteBio’s
Octet instruments. ForteBio’s Octet platform is based on the
company’s proprietary BioLayer Interferometry (BLI) technology,
which uses optical biosensors to measure multiple interactions in
parallel, without the use of detection agents. The Octet platform
consists of 8- and 16-channel instruments that accommodate 96- and
384-well assay formats. All Octet biosensors are designed to
simplify kinetic characterization and q
‘/>”/>
